Recent News

• 02.20.2025 - IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
• 02.19.2025 - IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
• 02.10.2025 - IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
• 12.19.2024 - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
• 12.10.2024 - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
• 11.25.2024 - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
• 11.07.2024 - Imunon Third Quarter 2024 Financial Results

Recent Filings

• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - 3 Initial statement of beneficial ownership of securities
• 02.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - 8-K Current report
• 02.10.2025 - EX-99.1 EX-99.1
• 01.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.27.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors